about
Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder SyndromePathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of DiseaseLong-term Outcomes of Augmentation Enterocystoplasty in Patients With End-Stage Bladder Diseases: A Single-Institute Experience Involving 102 Patients.Lower Levels of Urinary Nerve Growth Factor Might Predict Recurrent Urinary Tract Infections in WomenAbnormal Sensory Protein Expression and Urothelial Dysfunction in Ketamine-Related Cystitis in Humans.Therapeutic Efficacy of a New Procedure for Male Urinary Incontinence Combining a Suburethral Polypropylene Mesh and Cardiovascular Patch.Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From MedicationVideourodynamic analysis of the urethral sphincter overactivity and the poor relaxing pelvic floor muscles in women with voiding dysfunction.Urinary biomarkers in patients with detrusor underactivity with and without bladder function recovery.Urothelial Dysfunction and Chronic Inflammation are Associated With Increased Bladder Sensation in Patients With Chronic Renal Insufficiency.Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases.Role of Poor Urethral Sphincter Relaxation in Men with Voiding Dysfunction Refractory to α-blocker Therapy: Clinical Characteristics and Predictive Factors.Videourodynamic factors predictive of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity.Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxina injection in the treatment of interstitial cystitis refractory to conventional treatment-A prospective, randomized, clinical trial.A real-world experience with augmentation enterocystoplasty-High patient satisfaction with high complication rates.Histopathological characteristics of ketamine-associated uropathy and their clinical association.Vascular fibrinoid necrosis in the urinary bladder of ketamine abusers: A new finding that may provide a clue to the pathogenesis of ketamine-induced vesicopathy.Videourodynamic findings of lower urinary tract dysfunctions in men with persistent storage lower urinary tract symptoms after medical treatment.Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition.Urodynamic characteristics of detrusor underactivity in women with voiding dysfunction.Videourodynamic characteristics of interstitial cystitis/bladder pain syndrome-The role of bladder outlet dysfunction in the pathophysiologyEfficacy and safety of mirabegron, a β3 -adrenoceptor agonist, in patients with detrusor hyperactivity and impaired contractilityRepeat retropubic suburethral sling procedure is effective for recurrent female stress urinary incontinenceTherapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivitySafety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbiditiesClinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitisCurrent management of refractory overactive bladderMale patients with a higher frequency of nocturnal urinary episodes are more likely to benefit from alpha-blocker therapy for bothersome nocturiaHigher urge severity score predicts resumption of overactive bladder (OAB) medication following discontinuation of mirabegron treatment in patients with OABIntravesical injections of platelet-rich plasma is effective and safe in treatment of interstitial cystitis refractory to conventional treatment-A prospective clinical trialSurgical results in women with detrusor underactivity and stress urinary incontinence undergoing suburethral sling procedure-Predictive factors for successful outcomeChanges in sensory proteins in the bladder urothelium of patients with chronic kidney disease and end-stage renal diseaseAnxiety severity does not influence treatment outcomes in patients with interstitial cystitis/bladder pain syndromeLong-term outcome and symptom improvement in patients with interstitial cystitis/bladder pain syndrome with or without regular follow-up and treatmentPathophysiology of refractory overactive bladderPredictive factors for recovery of voiding function after transurethral prostate surgery in men with small prostate volume and very low detrusor contractilityUpregulation of neurotrophins and transforming growth factor-β expression in the bladder may lead to nerve hyperplasia and fibrosis in patients with severe ketamine-associated cystitisHigh incidence of lower urinary tract dysfunction in women with recurrent urinary tract infectionsBladder dysfunction does not affect long-term success rate of the retropubic suburethral sling procedure in women with stress urinary incontinencePain reduction realized with extracorporeal shock wave therapy for the treatment of symptoms associated with interstitial cystitis/bladder pain syndrome-A prospective, multicenter, randomized, double-blind, placebo-controlled study
P50
Q26770415-5F4D86AC-4BBB-4BD6-A9A4-A7FE23AE1DA6Q28079052-A46045B4-2610-4151-9E9B-041F7436E1FAQ33871826-642A1B5B-9E72-4DBB-964D-6214263A580BQ36760537-AAECDE9C-680C-4486-95CD-768E0E59C785Q37373406-08167A46-5DBF-4FE4-AE1A-1A410AB3F553Q40270972-35191BDA-0CDC-4EF4-8301-CE3E23EE2B2FQ40636667-B31ED9C7-F116-4A4B-B701-600964ABDBA6Q47814353-5E388AE4-3142-4C55-AC2E-09DC8F4C5DA2Q47997163-D4FE103C-B26D-4A74-9F7B-EA8BF0A172E7Q48132173-5B9A4A95-0D24-41A1-887D-CAC121DD348EQ48143949-F1813A7C-79EA-417E-8017-5CBA79EFECFDQ48176290-1EBCCDBD-E943-4F3C-B7BB-4B819EA7BB2AQ48197695-BA68E47E-85C0-48D5-8AE2-763BA0883185Q48249412-061C3E95-233F-4422-86CF-B395D94825E4Q49710506-AC161E75-D3ED-45A0-B1BF-628F8D09CD9FQ50020399-EFA2A60D-4DEF-4702-9C4B-0E8351815766Q52359591-6D7B6BD9-2214-42CB-B2FF-8A48D8C0EB38Q52692710-7892BF6F-53AE-4A4B-ACCB-CCEF5501919CQ55345274-7651F59A-16CA-4182-A788-B6FBC3BC0F30Q55490782-6543940A-84A6-41B5-85D9-ACBB0D7BEDFBQ87960306-07982C07-DB5D-4FCB-BAD4-8C1052A67BD5Q88480078-17415BD5-F9DA-4ADF-9D23-E7000CA0207DQ88491518-EFA9F0C4-DD37-429C-B177-AD268BB4E514Q88803123-CCF69FA2-C0C3-48F8-B146-2912A11EF8C4Q89185162-410FBF9F-1F89-4FA3-9D0B-A00023A84642Q89705017-061B4849-ED6D-40E7-9EB4-B75803A7414DQ89776631-00844580-9D7A-4C2C-845C-49C0B5A0D224Q90481091-15E1E868-3409-4041-9B99-C95F2C6BCC64Q90629005-5A5920B0-CD0C-4E18-85A7-0E80EEF4C4E7Q90696642-7638AD6D-5D68-400E-9BCB-876AFC7FD67CQ91133308-36D2FDD0-BD25-4EED-BBCD-936014C8DC90Q91350759-310497CC-DE7E-4078-A9EC-3795008FCCC0Q91790688-02931C98-DDA2-484C-AA3B-BD82B5BA42F3Q91921066-41696B10-6942-4B1B-BBB9-E5D9F696886FQ92546927-D5E3625A-3813-4B17-91E6-1138FA08263BQ92725435-CA3F1F78-2822-4189-A167-8B6B9A229B93Q92745239-830C516D-3F27-437B-8A65-CADB20AF7EF4Q93005295-00DCE10A-F277-42A7-B7CD-86B2D949BD91Q93366313-8EA2549E-24F3-4567-BAB1-EF69C13F47C1Q94566579-E381515B-92AD-4BFC-B66D-88A8355666D4
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Hann-Chorng Kuo
@en
Hann-Chorng Kuo
@nl
type
label
Hann-Chorng Kuo
@en
Hann-Chorng Kuo
@nl
prefLabel
Hann-Chorng Kuo
@en
Hann-Chorng Kuo
@nl
P31
P496
0000-0001-7165-4771